Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. DKSH Holding AG
  6. News
  7. Summary
    DKSH   CH0126673539

DKSH HOLDING AG

(DKSH)
  Report
Delayed Swiss Exchange  -  11:30 2022-12-02 am EST
72.05 CHF   +0.70%
11/29DKSH Unit to Provide Business Development Services for Keeling & Walker in Europe
MT
11/28DKSH Secures Distribution Deal for Nuance Pharma's Bentrio Nasal Spray in Hong Kong, Macau
MT
11/23DKSH Holdings (Malaysia)'s Profit, Revenue Rise in Q3
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

LEO Pharma and DKSH Partners to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis

09/29/2022 | 01:00am EST

DKSH Business has partnered with LEO Pharma to bring high-quality therapeutic products for dermatology and thrombosis to patients across Asia. Partnering in Hong Kong, Malaysia, Singapore, Taiwan, Thailand, Vietnam, and the Philippines, the two companies seek to solidify brand presence, grow market share, and ultimately improve patient health outcomes in the region. Skin diseases can cause serious physical and social discomfort for millions of patients around the world whereas thrombosis can affect anyone regardless of their age, race, gender, and ethnicity.

DKSH will support LEO Pharma by building dedicated sales and marketing teams on the ground in Asia and managing logistics and product distribution in these markets. The firm's experienced teams and broad distribution network will ensure LEO Pharma products reach modern trade, traditional trade, hospitals, clinics, and other medical channels, as well as patients in need across the region. LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society.

With decades of research and development to advance the science of dermatology, LEO Pharma now offers a wide range of innovative treatments and therapies for all skin disease severities as well as thrombosis.


ę S&P Capital IQ 2022
All news about DKSH HOLDING AG
11/29DKSH Unit to Provide Business Development Services for Keeling & Walker in Europe
MT
11/28DKSH Secures Distribution Deal for Nuance Pharma's Bentrio Nasal Spray in Hong Kong, Ma..
MT
11/23DKSH Holdings (Malaysia)'s Profit, Revenue Rise in Q3
MT
11/16DKSH Inks Exclusive Distribution Deal with Swedish Oat Supplier Lantmännen Functional F..
MT
11/16Dksh : Enters Exclusive Distribution Agreement With Lantmännen Functional Foods in Asia Pa..
PU
11/11Global markets live: SoftBank, Toshiba, Cisco, Apple, AstraZeneca...
MS
11/11Stifel Lowers Price Target on DKSH, Maintains Buy Recommendation
MT
11/07DKSH To Acquire Two Pharma Brands From Eisai
MT
11/07DKSH Continues Strengthening its Healthcare Own Brands Business With the Acquisition of..
EQ
11/07DKSH Holding AG signed an agreement to acquire Two pharma brands of Eisai.
CI
More news
Analyst Recommendations on DKSH HOLDING AG
More recommendations
Financials
Sales 2022 11 367 M 12 100 M 12 100 M
Net income 2022 212 M 226 M 226 M
Net cash 2022 48,9 M 52,0 M 52,0 M
P/E ratio 2022 22,2x
Yield 2022 2,93%
Capitalization 4 681 M 4 983 M 4 983 M
EV / Sales 2022 0,41x
EV / Sales 2023 0,38x
Nbr of Employees 31 160
Free-Float 49,3%
Chart DKSH HOLDING AG
Duration : Period :
DKSH Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DKSH HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 72,05 CHF
Average target price 82,00 CHF
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Stefan P. Butz Chief Executive Officer
Ido Wallach Chief Financial Officer
Marco Gadola Chairman
Sam Oh Chief Information Officer
Laurent Sigismondi Secretary, General Counsel & Head-Governance
Sector and Competitors
1st jan.Capi. (M$)
DKSH HOLDING AG-4.32%4 983
CINTAS CORPORATION4.37%46 968
TELEPERFORMANCE SE-41.71%14 153
EDENRED SE29.31%13 708
BUREAU VERITAS SA-12.71%12 081
LG CORP.2.10%9 978